Kallikreins are secreted serine proteases with important roles in human physiology. Human plasma kallikrein, encoded by the KLKB1 gene on locus 4q34-35, functions in the blood coagulation pathway, and in regulating blood pressure. The human tissue kallikrein and kallikrein-related peptidases (KLKs) have diverse expression patterns and physiological roles, including cancer-related processes such as cell growth regulation, angiogenesis, invasion, and metastasis. Prostate-specific antigen (PSA), the product of the KLK3 gene, is the most widely used biomarker in clinical practice today. A total of 15 KLKs are encoded by the largest contiguous cluster of protease genes in the human genome (19q13.3-13.4), which makes them ideal for evolutionary analysis of gene duplication events. Previous studies on the evolution of KLKs have traced mammalian homologs as well as a probable early origin of the family in aves, amphibia and reptilia. The aim of this study was to address the evolutionary and functional relationships between tissue KLKs and plasma kallikrein, and to examine the evolution of alternative splicing isoforms. Sequences of plasma and tissue kallikreins and their alternative transcripts were collected from the NCBI and Ensembl databases, and comprehensive phylogenetic analysis was performed by Bayesian as well as maximum likelihood methods. Plasma and tissue kallikreins exhibit high sequence similarity in the trypsin domain (>50%). Phylogenetic analysis indicates an early divergence of KLKB1, which groups closely with plasminogen, chymotrypsin, and complement factor D (CFD), in a monophyletic group distinct from trypsin and the tissue KLKs. Reconstruction of the earliest events leading to the diversification of the tissue KLKs is not well resolved, indicating rapid expansion in mammals. Alternative transcripts of each KLK gene show species-specific divergence, while examination of sequence conservation indicates that many annotated human KLK isoforms are missing the catalytic triad that is crucial for protease activity.
References
[1]
Lopez-Otin C, Bond JS (2008) Proteases: multifunctional enzymes in life and disease. J Biol Chem 283: 30433–30437.
[2]
Turk B (2006) Targeting proteases: successes, failures and future prospects. Nat Rev Drug Discov 5: 785–799.
[3]
Page MJ, Di Cera E (2008) Serine peptidases: classification, structure and function. Cell Mol Life Sci 65: 1220–1236.
[4]
Rawlings ND, Barrett AJ, Bateman A (2012) MEROPS: the database of proteolytic enzymes, their substrates and inhibitors. Nucleic Acids Res 40: D343–350.
[5]
Krem MM, Di Cera E (2001) Molecular markers of serine protease evolution. EMBO J 20: 3036–3045.
[6]
Borgono CA, Michael IP, Diamandis EP (2004) Human tissue kallikreins: physiologic roles and applications in cancer. Mol Cancer Res 2: 257–280.
[7]
Sainz IM, Pixley RA, Colman RW (2007) Fifty years of research on the plasma kallikrein-kinin system: from protein structure and function to cell biology and in-vivo pathophysiology. Thromb Haemost 98: 77–83.
[8]
Schmaier AH, McCrae KR (2007) The plasma kallikrein-kinin system: its evolution from contact activation. J Thromb Haemost 5: 2323–2329.
[9]
Kraut H, Frey EK, Werle E (1930) Der Nachweis eines Kreislaufhormon in der pankreasdruse. Hoppe-Seyler Z Physiol Chem 189: 97–106.
[10]
Madeddu P, Emanueli C, El-Dahr S (2007) Mechanisms of disease: the tissue kallikrein-kinin system in hypertension and vascular remodeling. Nat Clin Pract Nephrol 3: 208–221.
[11]
Watt KW, Lee PJ, M’Timkulu T, Chan WP, Loor R (1986) Human prostate-specific antigen: structural and functional similarity with serine proteases. Proc Natl Acad Sci U S A 83: 3166–3170.
[12]
Lundwall A, Lilja H (1987) Molecular cloning of human prostate specific antigen cDNA. FEBS Lett 214: 317–322.
[13]
Schedlich LJ, Bennetts BH, Morris BJ (1987) Primary structure of a human glandular kallikrein gene. DNA 6: 429–437.
[14]
Clements JA (1989) The glandular kallikrein family of enzymes: tissue-specific expression and hormonal regulation. Endocr Rev 10: 393–419.
[15]
Prensner JR, Rubin MA, Wei JT, Chinnaiyan AM (2012) Beyond PSA: the next generation of prostate cancer biomarkers. Sci Transl Med 4: 127rv123.
[16]
Yousef GM, Chang A, Scorilas A, Diamandis EP (2000) Genomic organization of the human kallikrein gene family on chromosome 19q13.3-q13.4. Biochem Biophys Res Commun 276: 125–133.
[17]
Lundwall A, Band V, Blaber M, Clements JA, Courty Y, et al. (2006) A comprehensive nomenclature for serine proteases with homology to tissue kallikreins. Biol Chem 387: 637–641.
[18]
Clements JA, Willemsen NM, Myers SA, Dong Y (2004) The tissue kallikrein family of serine proteases: functional roles in human disease and potential as clinical biomarkers. Crit Rev Clin Lab Sci 41: 265–312.
[19]
Debela M, Beaufort N, Magdolen V, Schechter NM, Craik CS, et al. (2008) Structures and specificity of the human kallikrein-related peptidases KLK 4, 5, 6, and 7. Biol Chem 389: 623–632.
[20]
Lawrence MG, Lai J, Clements JA (2010) Kallikreins on steroids: structure, function, and hormonal regulation of prostate-specific antigen and the extended kallikrein locus. Endocr Rev 31: 407–446.
[21]
Yousef GM, Kopolovic AD, Elliott MB, Diamandis EP (2003) Genomic overview of serine proteases. Biochem Biophys Res Commun 305: 28–36.
[22]
Pavlopoulou A, Pampalakis G, Michalopoulos I, Sotiropoulou G (2010) Evolutionary history of tissue kallikreins. PLoS One 5: e13781.
[23]
Elliott MB, Irwin DM, Diamandis EP (2006) In silico identification and Bayesian phylogenetic analysis of multiple new mammalian kallikrein gene families. Genomics 88: 591–599.
[24]
Clark NL, Swanson WJ (2005) Pervasive adaptive evolution in primate seminal proteins. PLoS Genet 1: e35.
[25]
Marques PI, Bernardino R, Fernandes T, Green ED, Hurle B, et al. (2012) Birth-and-death of KLK3 and KLK2 in primates: evolution driven by reproductive biology. Genome Biol Evol 4: 1331–1338.
[26]
Modrek B, Lee CJ (2003) Alternative splicing in the human, mouse and rat genomes is associated with an increased frequency of exon creation and/or loss. Nat Genet 34: 177–180.
[27]
Keren H, Lev-Maor G, Ast G (2010) Alternative splicing and evolution: diversification, exon definition and function. Nat Rev Genet 11: 345–355.
[28]
Kurlender L, Borgono C, Michael IP, Obiezu C, Elliott MB, et al. (2005) A survey of alternative transcripts of human tissue kallikrein genes. Biochim Biophys Acta 1755: 1–14.
[29]
Tan OL, Whitbread AK, Clements JA, Dong Y (2006) Kallikrein-related peptidase (KLK) family mRNA variants and protein isoforms in hormone-related cancers: do they have a function? Biol Chem 387: 697–705.
[30]
Marchler-Bauer A, Lu S, Anderson JB, Chitsaz F, Derbyshire MK, et al. (2011) CDD: a Conserved Domain Database for the functional annotation of proteins. Nucleic Acids Res 39: D225–229.
[31]
Letunic I, Doerks T, Bork P (2012) SMART 7: recent updates to the protein domain annotation resource. Nucleic Acids Res 40: D302–305.
[32]
Edgar RC (2004) MUSCLE: multiple sequence alignment with high accuracy and high throughput. Nucleic Acids Res 32: 1792–1797.
[33]
Waterhouse AM, Procter JB, Martin DM, Clamp M, Barton GJ (2009) Jalview Version 2–a multiple sequence alignment editor and analysis workbench. Bioinformatics 25: 1189–1191.
[34]
Maddison WP, Maddison DR (1989) Interactive analysis of phylogeny and character evolution using the computer program MacClade. Folia Primatol (Basel) 53: 190–202.
[35]
Abascal F, Zardoya R, Posada D (2005) ProtTest: selection of best-fit models of protein evolution. Bioinformatics 21: 2104–2105.
Guindon S, Gascuel O (2003) A simple, fast, and accurate algorithm to estimate large phylogenies by maximum likelihood. Syst Biol 52: 696–704.
[38]
Stamatakis A (2006) RAxML-VI-HPC: maximum likelihood-based phylogenetic analyses with thousands of taxa and mixed models. Bioinformatics 22: 2688–2690.
[39]
Herwald H, Renne T, Meijers JC, Chung DW, Page JD, et al. (1996) Mapping of the discontinuous kininogen binding site of prekallikrein. A distal binding segment is located in the heavy chain domain A4. J Biol Chem 271: 13061–13067.
[40]
Yousef GM, Diamandis EP (2001) The new human tissue kallikrein gene family: structure, function, and association to disease. Endocr Rev 22: 184–204.
[41]
Pampalakis G, Arampatzidou M, Amoutzias G, Kossida S, Sotiropoulou G (2008) Identification and analysis of mammalian KLK6 orthologue genes for prediction of physiological substrates. Comput Biol Chem 32: 111–121.
[42]
Angelopoulou K, Karagiannis GS (2009) The canine kallikrein-related peptidases 9 and 10: structural characterization and expression in mammary cancer. Mamm Genome 20: 758–767.
[43]
Angelopoulou K, Prassas I, Yousef GM (2009) The canine kallikrein-related peptidase 14: structural characterization, alternative splicing and differential expression in mammary cancer. Gene 446: 68–74.
[44]
Irimia M, Rukov JL, Roy SW, Vinther J, Garcia-Fernandez J (2009) Quantitative regulation of alternative splicing in evolution and development. Bioessays 31: 40–50.
[45]
Kim E, Goren A, Ast G (2008) Alternative splicing: current perspectives. Bioessays 30: 38–47.
[46]
Gharib WH, Robinson-Rechavi M (2011) When orthologs diverge between human and mouse. Brief Bioinform 12: 436–441.
[47]
Zambelli F, Pavesi G, Gissi C, Horner DS, Pesole G (2010) Assessment of orthologous splicing isoforms in human and mouse orthologous genes. BMC Genomics 11: 534.
[48]
Mudge JM, Frankish A, Fernandez-Banet J, Alioto T, Derrien T, et al. (2011) The origins, evolution, and functional potential of alternative splicing in vertebrates. Mol Biol Evol 28: 2949–2959.
[49]
Ezkurdia I, del Pozo A, Frankish A, Rodriguez JM, Harrow J, et al. (2012) Comparative proteomics reveals a significant bias toward alternative protein isoforms with conserved structure and function. Mol Biol Evol 29: 2265–2283.
[50]
Barbosa-Morais NL, Irimia M, Pan Q, Xiong HY, Gueroussov S, et al. (2012) The evolutionary landscape of alternative splicing in vertebrate species. Science 338: 1587–1593.
[51]
Merkin J, Russell C, Chen P, Burge CB (2012) Evolutionary dynamics of gene and isoform regulation in Mammalian tissues. Science 338: 1593–1599.
[52]
Xu Q, Lee C (2003) Discovery of novel splice forms and functional analysis of cancer-specific alternative splicing in human expressed sequences. Nucleic Acids Res 31: 5635–5643.
[53]
Lopez-Otin C, Overall CM (2002) Protease degradomics: a new challenge for proteomics. Nat Rev Mol Cell Biol 3: 509–519.
[54]
Luo LY, Soosaipillai A, Grass L, Diamandis EP (2006) Characterization of human kallikreins 6 and 10 in ascites fluid from ovarian cancer patients. Tumour Biol 27: 227–234.
[55]
Pepin D, Shao ZQ, Huppe G, Wakefield A, Chu CW, et al. (2011) Kallikreins 5, 6 and 10 differentially alter pathophysiology and overall survival in an ovarian cancer xenograft model. PLoS One 6: e26075.
[56]
Sun XY, Donald SP, Phang JM (2001) Testosterone and prostate specific antigen stimulate generation of reactive oxygen species in prostate cancer cells. Carcinogenesis 22: 1775–1780.
[57]
Williams SA, Singh P, Isaacs JT, Denmeade SR (2007) Does PSA play a role as a promoting agent during the initiation and/or progression of prostate cancer? Prostate 67: 312–329.
[58]
Williams SA, Jelinek CA, Litvinov I, Cotter RJ, Isaacs JT, et al. (2011) Enzymatically active prostate-specific antigen promotes growth of human prostate cancers. Prostate 71: 1595–1607.
